Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03822-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Mojtaba Zehtabi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: MicroRNAs, Genital Neoplasms, Female. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 128 Literaturangaben.
Abstract (Originalsprache)
MicroRNAs (miRNAs) have emerged as important regulators of gene expression in various biological processes, including cancer. miR-182-5p has gained attention for its potential implications in gynecologic cancers, including breast, ovarian, endometrial, and cervical cancers. miR-182-5p dysregulation has been associated with multiple facets of tumor biology in gynecologic cancers, including tumor initiation, progression, metastasis, and therapeutic response. Studies have highlighted its involvement in key signaling pathways and cellular processes that contribute to cancer development and progression. In addition, miR-182-5p has shown potential as a diagnostic and prognostic biomarker, with studies demonstrating its correlation with clinicopathological features and patient outcomes. Furthermore, the therapeutic potential of miR-182-5p is being explored in gynecologic cancers. Strategies such as miRNA mimics or inhibitors targeting miR-182-5p have shown promise in preclinical and early clinical studies. These approaches aim to modulate miR-182-5p expression, restoring normal cellular functions and potentially enhancing treatment responses. Understanding the biologic and clinical implications of miR-182-5p in gynecologic cancers is crucial for the development of targeted therapeutic strategies and personalized medicine approaches. Further investigations are needed to unravel the specific target genes and pathways regulated by miR-182-5p. It is important to consider the emerging biologic and clinical implications of miR-182-5p in gynecologic cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Obstetrics and Gynecology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Department of Human Morphology and Embryology, Division of Anatomy, Faculty of Medicine, Wrocław Medical University, Wrocław, Poland.
- Department of Veterinary Surgery, Institute of Veterinary Medicine, Nicolaus Copernicus University, Torun, Poland.
Zitieren
APA
Zehtabi, M., Ghaedrahmati, F., Dari, M. A. G., Moramezi, F., Kempisty, B., Mozdziak, P., & Farzaneh, M. (2024). Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03822-9
Vancouver
Zehtabi M, Ghaedrahmati F, Dari MAG, Moramezi F, Kempisty B, Mozdziak P, et al. Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03822-9
BibTeX
@article{Zehtabi2024,
author = {Zehtabi, Mojtaba and Ghaedrahmati, Farhoodeh and Dari, Mahrokh Abouali Gale and Moramezi, Farideh and Kempisty, Bartosz and Mozdziak, Paul and Farzaneh, Maryam},
title = {Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03822-9}
}
EUVIMED